NIP
PBYI icon

Nicholas Investment Partners’s Puma Biotechnology PBYI Stock Holding History

Nicholas Investment Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-45,453
Closed -$4.49M – 245
2017
Q4 		$4.49M Sell
45,453
-42,752
-48% -$4.78M 0.3% 103
2017
Q3 		$10.6M Buy
+88,205
New +$8.2M 0.73% 14
2015
Q2 		– Sell
-21,402
Closed -$5.05M – 325
2015
Q1 		$5.05M Buy
21,402
+4,669
+28% +$998K 0.32% 116
2014
Q4 		$3.17M Buy
16,733
+2,664
+19% +$591K 0.2% 196
2014
Q3 		$3.36M Buy
14,069
+1,228
+10% +$252K 0.21% 176
2014
Q2 		$848K Sell
12,841
-19,805
-61% -$1.41M 0.05% 266
2014
Q1 		$3.4M Buy
+32,646
New +$3.84M 0.28% 113

Other funds holding PBYI

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Nicholas Investment Partners's PBYI Position: Q1 2018 in Review

Nicholas Investment Partners sold out of Puma Biotechnology (PBYI) in Q1 2018, closing a stake of 45,453 shares — an estimated $4.49M sold.

Nicholas Investment Partners first reported a position in PBYI in Q1 2014 and held it in 7 quarters. The position peaked at $10.6M in Q3 2017. 178 funds tracked by Wall St. Rank hold PBYI as of Q1 2018.

  • Nicholas Investment Partners reported no remaining Puma Biotechnology position as of Q1 2018 after selling out during the quarter.
  • Nicholas Investment Partners sold 45,453 Puma Biotechnology shares in Q1 2018, an estimated $4.49M.
  • Nicholas Investment Partners first reported a position in Puma Biotechnology in Q1 2014 and held it in 7 quarters.
  • Nicholas Investment Partners's Puma Biotechnology position peaked at $10.6M in Q3 2017.
  • 178 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2018.

Based on Nicholas Investment Partners's 13F filing for Q1 2018, filed 15 May 2018.